Skip to Content
Merck
All Photos(2)

Key Documents

View All Documentation

SML3681

Sigma-Aldrich

ATM-3507

≥95% (HPLC)

Synonym(s):

ATM 3507, [3-​[[2,​3-​Dimethyl-​1-​[3-​(4-​methyl-​1-​piperazinyl)​propyl]​-​1H-​indol-​5-​yl]​oxy]​phenyl]​[4-​[2-​(4-​fluorophenyl)​ethyl]​-​1-​piperazinyl]​-methanone

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C37H46FN5O2
CAS Number:
1861449-70-8
Molecular Weight:
611.79
MDL number:
MFCD31657327
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥95% (HPLC)

form

powder

color

, Colorless to light brown

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Biochem/physiol Actions

ATM-3507 is a potent anti-tropomyosin agent that disables Tpm3.1 containing actin filaments. It exhibits potent cytotoxic activity against multiple neuroblastoma cancer cell lines. ATM-3507 sensitizes cancer cells to anti-microtubule agents. ATM-3507 significantly prolonged mitotic arrest induced by anti-microtubule agent vinorelbine.
Potent anti-tropomyosin agent that disables Tpm3.1 containing actin filaments

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000269646
0000269645
0000261956
0000269646
0000269645

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs
Molecular Cancer Therapeutics, 16(8), 1555-1565 (2017)
Molecular integration of the anti-tropomyosin compound ATM-3507 into the coiled coil overlap region of the cancer-associated Tpm3.1
Scientific Reports, 9(1), 11262-11262 (2019)
Xing Xu et al.
British journal of cancer, 125(2), 265-276 (2021-05-14)
Anti-microtubule agents are widely used to treat ovarian cancers, but the efficacy is often compromised by drug resistance. We investigated co-targeting the actin/tropomyosin cytoskeleton and microtubules to increase treatment efficacy in ovarian cancers and potentially overcome resistance. The presence of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service